



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Solifenacin-d<sub>7</sub> hydrochloride

<b>Cat. No.:</b>	HY-I0230S
<b>Molecular Formula:</b>	C <sub>23</sub> H <sub>20</sub> D <sub>7</sub> ClN <sub>2</sub> O <sub>2</sub>
<b>Molecular Weight:</b>	405.97
<b>Target:</b>	mAChR; Isotope-Labeled Compounds
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling; Others
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Solifenacin-d <sub>7</sub> (hydrochloride) is the deuterium labeled Solifenacin hydrochloride. Solifenacin hydrochloride (YM905 hydrochloride) is a muscarinic receptor antagonist, with pK <sub>i</sub> s of 7.6, 6.9 and 8.0 for M <sub>1</sub> , M <sub>2</sub> and M <sub>3</sub> receptors, respectively.		
<b>IC<sub>50</sub> &amp; Target</b>	mAChR2	mAChR1	mAChR3
<b>In Vitro</b>	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		

### REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-216.
- [2]. Ronald A. Smulders et al. Pharmacokinetics and Safety of Solifenacin Succinate in Healthy Young Men. *J Clin Pharmacol* September 2004 vol. 44 no. 9 1023-1033
- [3]. Krishna SR, Rao BM, Rao NS. A validated rapid stability-indicating method for the determination of related substances in solifenacin succinate by ultra-fast liquid chromatography. *J Chromatogr Sci.* 2010 Nov;48(10):807-10.
- [4]. Ohtake A, Sato S, Sasamata M, Miyata K. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: ameliorative effect of solifenacin succinate (Vesicare), a bladder-selective antimuscarinic agent, on overactive bladder symptoms, especially urgency episodes. *J Pharmacol Sci.* 2010;112(2):135-41. Epub 2010 Feb 4.
- [5]. Hoffstetter S, Leong FC. Solifenacin succinate for the treatment of overactive bladder. *Expert Opin Drug Metab Toxicol.* 2009 Mar;5(3):345-50.
- [6]. Choo MS, Lee JZ, Lee JB, Kim YH, Jung HC, Lee KS, Kim JC, Seo JT, Paick JS, Kim HJ, Na YG, Lee JG. Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study. *Int J Clin Pract.* 2008 Nov;62(11):1675-83.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA